Related Experiment Video
Updated: Jun 17, 2026
07:42
Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis
Published on: November 26, 2015
CASPASE-3 and CD-34 expression in prostate adenocarcinoma
Vicente Paulo da Motta1, Osvaldo Malafaia, Jurandir Marcondes Ribas-Filho
1Principles of Surgery Post-Graduate Program, Evangelical Medical School, Curitiba, Paraná, Brazil.
Revista Do Colegio Brasileiro De Cirurgioes
|January 16, 2010
Summary
This study found that while caspase-3 and CD-34 proteins are present in prostate adenocarcinoma, their expression levels do not correlate with tumor malignancy or Gleason
Area of Science:
- Oncology
- Molecular Pathology
- Biomarker Research
Background:
- Prostate adenocarcinoma is a significant cause of cancer-related mortality.
- Identifying reliable biomarkers for malignancy and prognosis is crucial for effective treatment strategies.
Purpose of the Study:
- To evaluate the expression of caspase-3 and CD-34 in prostate adenocarcinoma.
- To quantify these biomarkers within tumor cells.
- To determine the relationship between caspase-3 and CD-34 expression and tumor malignancy, including Gleason's score.
Main Methods:
- Immunohistochemical staining for caspase-3 and CD-34 in 38 human prostate cancer specimens.
- Quantification using the Samba 4000 Immuno System, measuring label index and optical density.
- Statistical analysis including univariate, bivariate, and correlation methods.
Main Results:
- Caspase-3 was detected in 73.5% and CD-34 in 100% of samples.
- High label index and low optical density were observed for both biomarkers.
- No statistically significant correlation was found between biomarker expression and Gleason's score or tumor severity.
Conclusions:
- Caspase-3 and CD-34 are present in prostate adenocarcinoma but do not serve as indicators of malignancy based on Gleason's score.
- Expression patterns (high label index, low optical density) were consistent but not correlated with tumor grade.
- Further research may be needed to explore other potential roles or correlations of these biomarkers in prostate cancer.
